Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, United States.
Novartis-Berkeley Translational Chemical Biology Institute, Berkeley, California 94720, United States.
ACS Chem Biol. 2024 Jan 19;19(1):58-68. doi: 10.1021/acschembio.3c00487. Epub 2024 Jan 8.
Targeted protein degradation has arisen as a powerful therapeutic modality for eliminating proteins. Thus far, most heterobifunctional proteolysis targeting chimeras (PROTACs) have utilized recruiters against substrate receptors of Cullin RING E3 ubiquitin ligases, such as cereblon and VHL. However, previous studies have surprisingly uncovered molecular glue degraders that exploit a CUL4 adaptor protein DDB1 to degrade neosubstrate proteins. Here, we sought to investigate whether DDB1 recruiters can be discovered that can be exploited for PROTAC applications. We utilized activity-based protein profiling and cysteine chemoproteomic screening to identify a covalent recruiter that targets C173 on DDB1 and exploited this recruiter to develop PROTACs against BRD4 and androgen receptor (AR). We demonstrated that the BRD4 PROTAC results in selective degradation of the short BRD4 isoform over the long isoform in a proteasome, NEDDylation, and DDB1-dependent manner. We also demonstrated degradation of AR with the AR PROTAC in prostate cancer cells. Our study demonstrated that covalent chemoproteomic approaches can be used to discover recruiters against Cullin RING adapter proteins and that these recruiters can be used for PROTAC applications to degrade neo-substrates.
靶向蛋白降解已成为消除蛋白质的一种强大治疗模式。到目前为止,大多数异双功能蛋白水解靶向嵌合体(PROTAC)已经利用了针对 Cullin RING E3 泛素连接酶底物受体的招募剂,如 cereblon 和 VHL。然而,之前的研究令人惊讶地发现了分子胶降解剂,它们利用 CUL4 衔接蛋白 DDB1 来降解新底物蛋白。在这里,我们试图研究是否可以发现可以用于 PROTAC 应用的 DDB1 招募剂。我们利用基于活性的蛋白质谱分析和半胱氨酸化学蛋白质组学筛选来鉴定靶向 DDB1 上 C173 的共价招募剂,并利用该招募剂开发针对 BRD4 和雄激素受体 (AR) 的 PROTAC。我们证明,BRD4 PROTAC 以蛋白酶体、NEDDylation 和 DDB1 依赖性方式选择性降解短 BRD4 同工型,而不是长同工型。我们还在前列腺癌细胞中证明了 AR PROTAC 的降解作用。我们的研究表明,共价化学蛋白质组学方法可用于发现针对 Cullin RING 衔接蛋白的招募剂,并且这些招募剂可用于 PROTAC 应用以降解新底物。